JB
BIVV

Julian Baker’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Julian Baker’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,249
Closed -$496K – 128
2017
Q2 		$496K Hold
8,249
– – ﹤0.01% 112
2017
Q1 		$449K Buy
+8,249
New +$406K ﹤0.01% 112

Other funds holding BIVV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Julian Baker's BIVV Position: Q3 2017 in Review

Julian Baker sold out of Bioverativ Inc. Common Stock (BIVV) in Q3 2017, closing a stake of 8,249 shares — an estimated $496K sold.

Julian Baker first reported a position in BIVV in Q1 2017 and held it in 2 quarters. The position peaked at $496K in Q2 2017. 446 funds tracked by Wall St. Rank hold BIVV as of Q3 2017.

  • Julian Baker reported no remaining Bioverativ Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Julian Baker sold 8,249 Bioverativ Inc. Common Stock shares in Q3 2017, an estimated $496K.
  • Julian Baker first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Julian Baker's Bioverativ Inc. Common Stock position peaked at $496K in Q2 2017.
  • 446 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q3 2017.

Based on Baker Bros. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.